A Phase 4 interventional study of Faricimab in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche. Active, not recruiting at 67 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.
Among the 14 studies testing faricimab in Macular Degeneration, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 4, and was the 8th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:
Junyeop Lee · Sites in Korea, Republic of
Ages 50+
Biobizkaia Health Research Institute · Sites in Spain
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Singapore National Eye Centre · Sites in Singapore
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
By country, each count listing its studies:
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2013; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 274 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 57 across the 14 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 13th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 in phase 4, and was the 29th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing faricimab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Inclusion Criteria for Study Eye:
Exclusion Criteria:
Ocular Exclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Fellow (Non-Study) Eye:
Ocular Exclusion for Both Eyes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab
Drug: Faricimab
Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
Also known as: RO6867461, VABYSMO®
Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52
Time frame: Baseline and average of Weeks 44, 48, and 52
Change from Baseline in BCVA Score Averaged Over Weeks 92, 96, and 100
Time frame: Baseline and average of Weeks 92, 96, and 100
Change from Baseline in BCVA Score Over Time
Time frame: From Baseline to Week 100
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time
Time frame: From Baseline to Week 100
Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Time frame: From Baseline to Week 100
Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Time frame: From Baseline to Week 100
Change from Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44, 48, and 52
Time frame: Baseline and average of Weeks 44, 48, and 52
Change from Baseline in CST Averaged Over Weeks 92, 96, and 100
Time frame: Baseline and average of Weeks 92, 96, and 100
Change from Baseline in CST Over Time
Time frame: From Baseline to Week 100
Percentage of Participants on Different Treatment Intervals at Weeks 52 and 100
Time frame: Weeks 52 and 100
Incidence and Severity of Ocular Adverse Events
Time frame: From first study treatment to Week 100
Incidence and Severity of Non-Ocular Adverse Events
Time frame: From first study treatment to Week 100
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Oct 2026, 19 months.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 19 months is below that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab